🧩Solve the latest #KidneyKolumns crossword: NEPHRONS & NEOPLASIA 🦀🫘Test your knowledge of Onconephrology! 🌟First 5 correct entries will receive a shout-out in the next edition of @isn-india.bsky.social Newsletter Kidney Kolumns 🔗https://puzzel.org/en/crossword/play?p=-OvuDKCWauB8uMBaYYMQ

And @nejm.org retracts ADVOCATE based on the FDA uncovering and 2 academic authors asking for article to be pulled. (Good on them!) www.nejm.org/doi/10.1056/... h/t @drjmluther.bsky.social #Avacopan #vasculitis

#NephJC Consensus From GEMRITUX, MENTOR, STARMEN, RI-CYCLO & MAJESTY- the signal remains consistent: ✅ Anti-CD20 therapy works ✅ Remissions are durable ✅ Relapses are lower than CNIs Check out anti-CD20 trials in pMN by @nephroseeker.medsky.social 👇 #NephJC #TenPostNephJC #NephTwitter #NephSky

Among participants with rifampicin-resistant tuberculosis, a 6-month treatment strategy consisting of bedaquiline, linezolid, delamanid, and levofloxacin or clofazimine was noninferior to the standard treatment. Full phase 3 BEAT Tuberculosis trial results: https://nej.md/4w7aekw

🚨New 🩳 by @nephroseeker.medsky.social eGFRcr, eGFRcys, eGFRcr-cys, mGFR... What does mGFR teach us about estimates and outcomes? #NephSky #MedSky #NephJC www.nephjc.com/news/2026/short/measuredgfr

Took us more than 10 years to get this to this stage AVF versus catheters - doing an RCT was difficult and we learnt a lot. Hope our community also does?

Quantitative Serological Detection of NELL1 Autoantibodies in Membranous Nephropathy - Kidney International www.kidney-international.org/article/S008...

Probenicid affects urate pathway and decreasing cyst growth in ADPKD Waiting to see how this area evolves in the future ! Dr Fouad Chebib is an inspiration..changing the landscape of ADPKD treatment!

Huge effect of mTOR inhibition (sirolimus, everolimus?) in tuberous sclerosis academic.oup.com/ckj/article/... in @ckj-era.bsky.social Not an RCT of course - rare disease and all that! Via @dguerrot.bsky.social on LI #NephSky

Unlike COMPASS, TRACK demonstrates rivaroxaban doesn’t have the same CV benefit in CKD jamanetwork.com/journals/jam... Simultaneous pubs from #ERA26

Simulpub number 6 at #ERA26 Obi beats tacrolimus in membranous nephropathy www.nejm.org/doi/full/10.... in NEJM No surprise after MENTOR

21/F G3P0LOA2 14weeks POG. Two 1st trimester abortions-cause? Incidental detection of urine alb. No HT 24 HR UP =1.3g/d s.creat=0.7 mg/dL Urine- no RBCs APLA,ANA negative, C3, C4 normal. Wud u do a biopsy ? #NephSky @shilpajesudason.bsky.social @silvishah.bsky.social @priti899.bsky.social

✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...

1/10 Welcome to #TenPostNephJC Can we move beyond slowing CKD → to actually repairing the kidney? Last #NephJC we discussed Rilparencel, a renal autologous cell therapy (REACT) infusion and its effect on eGFR slope.

Hi everyone! Pallavi from New Delhi. No COI #NephJC Using flozins occasionally in transplants-mostly in those with proteinuria+-PTDM.

moving on from IgAN to FSGS: BI 764198 a TRPC6 inhibitor reduces proteinuria in an N = 67 phase 2 RCT www.thelancet.com/journals/lan... in @thelancet.com #NephSky

Editors’ Choice 2025: Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial This phase 2 trial tested ravulizumab, a complement C5 inhibitor, in adults with IgA nephropathy. Check out the paper here: kidney.pub/JASN0534

Sodium-Glucose Cotransporter-2 Inhibitors #SGLT2i and #Cardiorenal Events in #Nonalbuminuric Kidney Disease #VisualAbstract by Augusto Cesar S Santos Jr https://www.kireports.org/article/S2468-0249(25)00774-0/fulltext#SGLT2i#Cardiorenal#Nonalbuminuric#VisualAbstractwhuang0824

1/10 Last #NephJC we discussed Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN #TenPostNephJC Given the central role of complement dysregulation in C3 glomerulonephritis, we assessed whether complement-targeted therapies confer therapeutic benefit. www.nejm.org/doi/full/10....

Hi everyone! Pallavi from New Delhi. No COI #NephJC

Check out the VA for VALIANT from @nephromommy-akshu.bsky.social #NephJC www.nephjc.com/news/2026/1/11/valiant-the-visual-abstract

The LIBERATE-D VA by @sejalplakhani.bsky.social Should we break the pattern of thrice weekly dialysis in AKI-D? #NephJC #NephSky www.nephjc.com/news/liberateva

Join us for the last #NephJC of 2025, 12/16/25 at 9pm EST!🥳 How soon should we withhold dialysis in AKI? We're discussing the LIBERATE-D trial #NephSky This one might just change your mind 🧠🧠 Blog by @msocomd.bsky.social and @sejalplakhani.bsky.social www.nephjc.com/news/liberated-aki

1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC Read the article 👇 www.nejm.org/doi/10....#NephJC

T3f: #NephJC Whether dual inhibition APRIL/BAFF offers a longer-term advantage over APRIL-selective therapy remains a key question that only eGFR slope data will answer. APRIL-selective therapy also prevents its action at other receptors (BCMA). Do you think either has the advantage?

T0k: #NephJC The 96-week extension demonstrated durability: ⬇️proteinuria fell 52% ⬇️Gd-IgA1 dropped 66% ⬇️hematuria declined 75% ⬇️ annualized eGFR slope was −0.6 mL/min/1.73 m² ⚠️Safety: mild injection-site reactions and transient infections pubmed.ncbi.nlm.nih....#NephJC

Hi everyone! Pallavi from New Delhi ! The day light saving change in #NephJC doesn't help when in India - approaching time to leave for work..will be lurking . Excited about targeted therapeutic approaches in IgAN . No COI.

Day light saving always confuses me. One hour early for #NephJC 🥲 and wondering where everyone else is! 😂

Check out the awesome visual abstract by @salinesolut.bsky.social Attacking the origins of IgAN with atacicept ⚔️ www.nephjc.com/news/2025/11/17/origin-3-the-visual-abstract

APRIL/BAFF inhibition: 🎯💊🩺 Trials are under way on this pathway, which promise to get to the root cause of IgAN. However, with great innovation comes…greater confusion. Sequence of treatment, cost, and side effects will need to be considered when increasing immunosuppression. #NephJC

BTW super interesting basket trial from India (Ongoing) bsky.app/profile/hswa... Maybe they can eventually add a povetacicept arm 😏 #NephJC

Treatment Approach: 💊 Novel therapies for IgAN have shifted the paradigm to a bi-pronged approach. a) Generic responses to HTN/proteinuria b) Fundamental drivers of nephron loss by reducing the formation of aberrant IgA molecules & the maladaptive mechanisms that contribute to CKD. #NephJC

Let’s recapitulate the history and evidence-based developments of IgA Nephropathy. We’ve known about the pathologic etiology for decades, however there was a huge therapeutic plateau until quite recently. 💉💊 In the last few years, new therapies are coming up rapidly. #NephJC

The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky ✍️Summary by @thekidneywhisperer.bsky.social and @glomerican.bsky.social www.nephjc.com/news/igan-kd...

⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline 🎨 Nice visual summary by @roxnonna23.bsky.social www.nephjc.com/news/2025/10...

Apart from myeloma and MGRS , what other diseases should we think of in case of increased UPCR with no albumunuria in urine analysis. Urine alb- trace UPCR-5.2 SIFE,SFLC - normal @askrenal.bsky.social #askrenal #Nephsky

1/10 Last #NephJC we tried to answer the question whether protein supplementation increases health related QoL 🥩💊#TenPostNephJC . Read the article 👇 pubmed.ncbi.nlm.nih....#NephJC

⏰30 min before the #NephJC chat Let's learn about the Gurus who paved the path to make kidney transplant “Mission Impossible to Mission Possible” with their research.

Hello everyone! Pallavi here from New Delhi. No COI. #NephJC

www.nejm.org/doi/full/10.... There’s some trial data on prevention of albuminuria #nephjc

T2l Initiation of 2 first-line agents is still recommended for Stage 2 HTN but there is a new emphasis on using single-pill combinations. One pill goes down easier than two! What’s your favorite combo pill? Not using combo pills – what’s holding you back? #NephJC www.thelancet.com/jo...#NephJC

Check out the insightful VA that makes sense of the updates 🧠 #nephjc VA by @sejalplakhani.bsky.social

Hi everyone! Pallavi from New Delhi. no COI. #NephJc

Finally, the concurrent results of the ALCHEMIST trial (www.sciencedirect.co...) also showed that spironolactone did not reduce major cardiovascular events in older, high-risk hemodialysis patients. #NephJC Infographic by @nephroseeker.medsky.socia

Hi everyone! Pallavi from New Delhi, joining #Nephjc after a long hiatus. lurking today .. No COI.

The #NephJC editorial team knows that plenty of papers deserve attention between our bi-monthly, full-length discussions ✨Enter #NephJCShorts - quick hits with a critical eye 🦅 on high-impact reads www.nephjc.com/news/nephjc-... #MedSky #NephSky

Hi everyone! Good morning from Kerala, God's own country. will be lurking today. COI: flozinator >> RAASblocker

From Rivka Galchen’s article in @newyorker.com: “The kidney, a tremendously under-celebrated organ, basically does four-dimensional sudoku with ions.” And that’s how I’m going to explain it from now on.

Hilarious (and sobering) essay on the use of AI in medical research & manuscript writing Read the whole thing! John Daugirdas has been on the cutting edge of tech in meded before #MedEd was thing onlinelibrary.wiley.com/doi/10.1111/... #MedSky #NephSky